DCVax-L exemption approval in Germany for Glioblastoma - Northwest Bio

Northwest Biotherapeutics a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, announced that it has received approval from the Paul Ehrlich Institute of a "Hospital Exemption" early access program under Section 4b of the German Drug Law. Under this Hospital Exemption, NW Bio may provide DCVax-L to patients for the treatment of any glioma brain cancers (both Glioblastoma multiforme and lower grade gliomas), both newly diagnosed and recurrent, outside of the Company's clinical trial and charge full price. The patients may be from Germany or elsewhere. This approval has a term of five years, and can be re-applied for and re-issued at the end of that period.

This immunotherapy is in Phase III trials in the US and UK.